Slade A K, Sadoul N, Shapiro L, Chojnowska L, Simon J P, Saumarez R C, Dodinot B, Camm A J, McKenna W J, Aliot E
Department of Cardiological Sciences, St George's Hospital Medical School, London.
Heart. 1996 Jan;75(1):44-9. doi: 10.1136/hrt.75.1.44.
DDD pacing has been advocated as an effective treatment for drug refractory obstructive hypertrophic cardiomyopathy. This study reports the outcome of pacing in 56 patients with refractory symptoms referred to four tertiary centres.
Core data on symptoms, drug burden, and left ventricular outflow tract gradient were recorded. Patients underwent a temporary pacing study with optimisation of the atrioventricular (AV) delay for greatest gradient reduction without haemodynamic compromise. Patients were assessed after implantation in terms of changes in symptoms, drug load, and outflow tract gradient.
56 patients underwent pacing assessment. The mean (SD) left ventricular outflow tract gradient before pacing was 78 (31) mm Hg. At temporary study the mean (SD) left ventricular outflow tract gradient was 38 (24) mm Hg with a median (range) optimised sensed AV delay of 65 (25-125) ms. Fifty three patients were implanted and followed up for a mean (SD) of 11 (11) months. The median (range) programmed sensed AV delay was 60 (31-200) ms. Left ventricular outflow tract gradient at follow up was 36 (25) mm Hg. Forty four patients had improved functional class. Although a correlation (r = 0.69) was shown between acute and chronic left ventricular outflow tract gradient reduction, there was no correlation between magnitude of gradient reduction and functional improvement, and no appreciable change in pharmacological burden.
This series confirms symptomatic improvement after DDD pacing in hypertrophic cardiomyopathy. There remains, however, a discrepancy between perceived symptomatic benefit and modest objective improvement. Furthermore, the optimal outcome has been achieved only with continued pharmacological treatment. Current methods of temporary evaluation do not predict functional outcome which seems to be independent of the magnitude of gradient reduction.
双腔(DDD)起搏已被提倡作为药物难治性梗阻性肥厚型心肌病的一种有效治疗方法。本研究报告了转诊至四个三级中心的56例难治性症状患者的起搏治疗结果。
记录症状、药物负担和左心室流出道梯度的核心数据。患者接受临时起搏研究,优化房室(AV)延迟以最大程度降低梯度且不影响血流动力学。植入后对患者进行症状、药物负荷和流出道梯度变化方面的评估。
56例患者接受了起搏评估。起搏前左心室流出道平均(标准差)梯度为78(31)mmHg。临时研究时左心室流出道平均(标准差)梯度为38(24)mmHg,优化后的感知AV延迟中位数(范围)为65(25 - 125)ms。53例患者植入起搏器并随访,平均(标准差)随访11(11)个月。程控感知AV延迟中位数(范围)为60(31 - 200)ms。随访时左心室流出道梯度为36(25)mmHg。44例患者的心功能分级得到改善。尽管急性和慢性左心室流出道梯度降低之间存在相关性(r = 0.69),但梯度降低幅度与功能改善之间无相关性,药物负担也无明显变化。
本系列研究证实肥厚型心肌病患者行DDD起搏后症状改善。然而,在感知到的症状获益与适度的客观改善之间仍存在差异。此外,仅持续药物治疗才能取得最佳效果。目前的临时评估方法无法预测功能结局,功能结局似乎与梯度降低幅度无关。